昔日明星股，又被“猛砍”估值！

Core Viewpoint - The valuation of NuoHui Health has been drastically reduced by multiple public funds, with Da Cheng Fund setting the latest valuation at HKD 0.55 per share, marking the lowest valuation to date [2][3][4]. Group 1: Valuation Adjustments - Da Cheng Fund announced a new valuation of HKD 0.55 per share for NuoHui Health, effective from July 31, 2025, following a series of previous adjustments [3][4]. - The valuation of NuoHui Health has been cut from HKD 14.14 per share before its suspension to HKD 0.55, representing a decline of over 96% [4]. - Other public funds, including Baoying, Penghua, and Bosera, have also significantly reduced their valuations of NuoHui Health, with Bosera valuing it at HKD 3.33 per share [4][6]. Group 2: Background and Context - NuoHui Health was once a leading stock in the Hong Kong market, known for cancer screening, with a market capitalization exceeding HKD 40 billion [6]. - The company has been suspended since March 2024 due to allegations of financial fraud and audit concerns raised by Deloitte [6][7]. - The inability to timely disclose financial reports has led to ongoing valuation adjustments by various fund companies since mid-2023 [6]. Group 3: Industry Insights - The continuous downward adjustment of NuoHui Health's valuation reflects a generally pessimistic outlook on its prospects for resuming trading and heightened market vigilance regarding potential risks [7]. - Fund managers adjust valuations to ensure the fair value of fund net assets and protect investor interests, especially when market prices do not accurately reflect intrinsic value [5][7]. - The actions taken by fund companies indicate a trend towards improved risk monitoring and control within the industry [8][9].